Hong Kong, China as regulatory member of International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use marks key step towards developing into international health and medical innovation hub
The Health Bureau announced today (November 20) that Hong Kong, China has formally joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) as a regulatory member. The ICH is a key international platform for the harmonisation of technical standards for drug regulation. Hong Kong's formal accession to ICH membership signifies international recognition of its drug research and development (R&D) as well as regulatory standards. It will help further promote the development of the capabilities and mechanisms for the "primary evaluation" of innovative drugs, enable Hong Kong to participate deeply in the formulation of international rules on drug R&D and registration, and accelerate the development of Hong Kong into an international health and medical innovation hub. At its assembly meeting held in Czech Republic on November 17, 2026, the ICH approved the admission of Hong Kong, China (represented by the Pharmacy and Poisons Board of Hong Kong) as its 20th regulatory member. Other ICH regulatory members include the National Medical Products Administration of China and the regulatory authorities of Europe, Switzerland, the United
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


